Haemonetics Q4 2022 Earnings Report
Key Takeaways
Haemonetics reported a strong fourth quarter, with revenue up 17.8% to $265 million. The company saw growth across its business units, particularly in Hospital, and managed to mitigate inflationary pressures through its Operational Excellence Program. Adjusted earnings per diluted share increased by 41.3% to $0.65.
Revenue increased by 17.8% to $265 million.
Organic revenue increased by 18.9%.
Adjusted earnings per diluted share increased by 41.3% to $0.65.
Operating income was $19.2 million, compared to an operating loss of $21.2 million in the same period last year.
Haemonetics
Haemonetics
Haemonetics Revenue by Segment
Forward Guidance
The Company issued its fiscal 2023 GAAP total revenue growth guidance of 5 – 9% and organic revenue growth guidance as follows:Organic1Total revenue6 - 10%Plasma revenue7 - 12%Hospital Revenue16 - 19%Blood Center revenue(4 - 7%)
Revenue & Expenses
Visualization of income flow from segment revenue to net income